| AstraZeneca gets fresh designation for Enhertu w... | 22-Dec-2025 | ShareCast |
| Enhertu granted BTD for post-neoadjuvant early BC | 22-Dec-2025 | ShareCast |
| Update on LATIFY Phase III trial of ceralasertib | 22-Dec-2025 | ShareCast |
| Director/PDMR Shareholding | 19-Dec-2025 | ShareCast |
| AstraZeneca chalks up dual regulatory wins in ca... | 16-Dec-2025 | ShareCast |
| Total Voting Rights | 02-Jan-2026 | 15:00 | RNS |
| Director/PDMR Shareholding | 22-Dec-2025 | 11:00 | RNS |
| Director/PDMR Shareholding | 22-Dec-2025 | 11:00 | RNS |
| Enhertu granted BTD for post-neoadjuvant early BC | 22-Dec-2025 | 07:30 | RNS |
| Update on LATIFY Phase III trial of ceralasertib | 22-Dec-2025 | 07:00 | RNS |
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 13,592.00p |
| Change Today | -198.00p |
| % Change | -1.44 % |
| 52 Week High | 14,148.00 |
| 52 Week Low | 9,667.00 |
| Volume | 3,894,707 |
| Shares Issued | 1,550.91m |
| Market Cap | £210,799m |
| Beta | 1.27 |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Latest | Previous | |
|---|---|---|
| 1st Interim | 2nd Interim | |
| Ex-Div | 07-Aug-25 | 20-Feb-25 |
| Paid | 08-Sep-25 | 24-Mar-25 |
| Amount | 103.00¢ | 210.00¢ |
| Time | Volume / Share Price |
| 14:55 | 0 @ 13,700.00p |
| 14:55 | 0 @ 13,700.00p |
| 14:55 | 0 @ 13,700.00p |
| 14:55 | 0 @ 13,696.00p |
| 14:55 | 0 @ 13,696.00p |
You are here: research